The Effect of Radiofrequency Exposure on the Cytotoxic Activity of Sunitinib and a Novel Sunitinib-Class Compound 4, in Colorectal Cancer Cells
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27135953 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Ayse Erol Bozkurt und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Biology, Istanbul Faculty of Medicine, Istanbul University, 34093 Istanbul, Turkey. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Indoles, Pyrroles, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Istanbul University, Istanbul University Scientific Research Projects Coordination Unit.
Abstract (Originalsprache)
Achieving optimal therapeutic efficacy in colorectal cancer (CRC) remains challenging, highlighting the need for novel treatment strategies. This study evaluated whether radiofrequency (RF) hyperthermia enhances the anticancer effects of sunitinib malate and a newly synthesized tyrosine kinase (TK) inhibitor (compound 4). HCT116 CRC cells and BEAS-2B normal epithelial cells were treated with increasing concentrations of both agents in the presence or absence of RF exposure using a mobile RF device. Cell viability and death were assessed by MTT assay and flow cytometry (Annexin V/PI). RF exposure was associated with reduced viability and increased cell death in HCT116 cells (p < 0.05). Flow cytometric analysis confirmed that RF exposure may contribute to the observed reduction in viability. Notably, the findings suggest a possible beneficial contribution of RF hyperthermia to the observed cytotoxic effects, particularly near the IC50 concentration. In contrast, BEAS-2B cells maintained high viability with no significant changes (p > 0.05). These findings suggest that RF exposure may contribute to the observed cytotoxic responses in CRC cells while exerting limited effects on non-malignant cells, suggesting a promising strategy for targeted therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Biology, Istanbul Faculty of Medicine, Istanbul University, 34093 Istanbul, Turkey.
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Istanbul Health and Technology University, 34275 Istanbul, Turkey.
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Istanbul University, 34116 Istanbul, Turkey.
- Department of Engineering Sciences, Faculty of Engineering, Istanbul University-Cerrahpaşa, 34320 Istanbul, Turkey.
- Department of Medical Oncology, School of Medicine, Altinbas University, 34147 Istanbul, Turkey.
- ChemoThermia Oncology Center, 34295 Istanbul, Turkey.
ORCID-Profile: Ayse Erol Bozkurt, Mediha Suleymanoglu, Serap Kuruca
Förderung
- Istanbul University
- Istanbul University Scientific Research Projects Coordination Unit
Zitieren
APA
Erol Bozkurt, A., Suleymanoglu, M., Cinek, T., Karali, N., Ballikaya, S., Iyikesici, M. S., & Kuruca, S. (2026). The Effect of Radiofrequency Exposure on the Cytotoxic Activity of Sunitinib and a Novel Sunitinib-Class Compound 4, in Colorectal Cancer Cells. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27135953
Vancouver
Erol Bozkurt A, Suleymanoglu M, Cinek T, Karali N, Ballikaya S, Iyikesici MS, et al. The Effect of Radiofrequency Exposure on the Cytotoxic Activity of Sunitinib and a Novel Sunitinib-Class Compound 4, in Colorectal Cancer Cells. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27135953
BibTeX
@article{ErolBozkurt2026,
author = {Erol Bozkurt, Ayse and Suleymanoglu, Mediha and Cinek, Tugce and Karali, Nilgun and Ballikaya, Sedat and Iyikesici, Mehmet Salih and Kuruca, Serap},
title = {The Effect of Radiofrequency Exposure on the Cytotoxic Activity of Sunitinib and a Novel Sunitinib-Class Compound 4, in Colorectal Cancer Cells},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27135953}
}
EUVIMED